BioPharmSignal logoBioPharmSignal

Biotech News

PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial

PMV Pharmaceuticals (PMVP)PMV PharmaceuticalsClinical readout

46% ORR observed among 76 evaluable patients in the ovarian cancer cohort with a median duration of response of 10.0 months Recent FDA interaction supports NDA submission strategy for accelerated approval of rezatapopt for platinum-resistant/refractory ovarian cancer, with submission planned in

Related news

LYELLyell Immunopharma2026-09-10 20:05 EST

Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer

INBXInhibrx2026-09-08 11:30 EST

Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study

RVMDRevolution Medicines2026-10-05 12:00 EST

Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer

PMVPPMV Pharmaceuticals2026-10-05 12:00 EST

PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors

CGEMCullinan Therapeutics, Inc.2026-09-10 17:00 EST

Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

PMVPPMV Pharmaceuticals2026-09-08 12:00 EST

PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer

BMYBMYBristol-Myers Squibb Company2026-09-08 10:59 EST

Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...

REGNRegeneron Pharmaceuticals2026-10-01 15:30 EST

Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss

IDYAIDEAYA Biosciences2026-09-09 10:00 EST

IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma

FATEFate Therapeutics2026-08-14 11:00 EST

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

View all latest news

PMV Pharmaceuticals

Mutant-p53 Precision Oncology PMV Pharmaceuticals develops small-molecule precision therapies that target specific mutations in the p53 tumor-suppressor protein. Its platform is designed to restore the normal cancer-suppressing function of structurally altered p53 proteins, addressing mutations found across multiple solid-tumor...

Recent company news

PMVPPMV Pharmaceuticals2026-10-05 12:00 EST

PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors

PMVPPMV Pharmaceuticals2026-09-08 12:00 EST

PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer

PMVPPMV Pharmaceuticals2026-09-01 03:04 EST

PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities

PMVPPMV Pharmaceuticals2026-08-31 20:02 EST

PMV Pharma Announces Proposed Public Offering of Securities

PMVPPMV Pharmaceuticals2026-08-31 20:01 EST

PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial

Stock data

Close
1.61 USD
Market cap
62.93M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States